Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs

Biochemical and Biophysical Research Communications

Volumn 468, Issue 3, 2015, Pages 490-497

  Szebeni, Janos ^a   Storm, Gert ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Adverse drug reactions; Anaphylatoxins; Anaphylaxis; C5a; Complement; Pigs; Pseudoallergy

Indexed keywords

DOXORUBICIN; LIPOSOME; GENERIC DRUG; NANOCAPSULE;

ALGORITHM; ALLERGIC REACTION; ALLERGY TEST; BIOEQUIVALENCE; C ACTIVATION RELATED PSEUDOALLERGY; COMPLEMENT ACTIVATION; HUMAN; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; NANOMEDICINE; NONHUMAN; PORCINE MODEL; PRIORITY JOURNAL; REVIEW; ADVERSE EFFECTS; DRUG EFFECTS; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; IMMUNOLOGY; THERAPEUTIC EQUIVALENCE;

COMPLEMENT ACTIVATION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUGS, GENERIC; LIPOSOMES; NANOCAPSULES; THERAPEUTIC EQUIVALENCY;

EID: 84951569729     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.06.177     Document Type: Review

References (81)

1. D.J.A. Crommelin, J.M. Metselaar, and G. Storm Liposomes: the science and the regulatory landscape D.J.A. Crommelin, J.S.B. de Vlieger, Non-Biological Complex Drugs: the Science and the Regulatory Landscape AAPS Advances in the Pharmaceutical Sciences Series 20, AAPSPRESS 2015 Springer 77 106
2. www.bharatserums.com/product/neurology/AMPHONEX%2050mg%20%28Lyo%29%20Pack%20Insert%20for%20Domestic-2013-04-06-07-45-20-893.pdf (2014).
3. http://www.tlcbio.com/upload/media/investor/%E6%B3%95%E8%AA%AA%E6%9C%83%E7%B0%A1%E5%A0%B1/Company%20Yearly%20Update%20for%20201403v5.pdf (2015).
4. X. Zhang, N. Zheng, R.A. Lionberger, and L.X. Yu Innovative approaches for demonstration of bioequivalence: the US FDA perspective Ther. Deliv. 4 2013 725 740
5. C. Holloway, J. Mueller-Berghaus, B.S. Lima, S.L. Lee, J.S. Wyatt, J.M. Nicholas, and D.J. Crommelin Scientific considerations for complex drugs in light of established and emerging regulatory guidance Ann. N. Y. Acad. Sci. 1276 2012 26 36
6. G. Borchard, B. Fluhmann, and S. Muhlebach Nanoparticle iron medicinal products - Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies Regul. Toxicol. Pharmacol. 64 2012 324 328
7. EMA Committee for Human Medicinal Products (CHMP): Reflection Paper on the Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal Product 2013 EMA/CHMP/806058/2009/Rev. 02 www.ema.europa.eu/docs/enGB/document./WC500140351.pdf
8. FDA Voluntary Shutdown of Ben Venue Laboratories 2011 http://www.fda.gov/Drugs/DrugSafety/ucm281782.htm
9. EMA EMA Questions and Answers on the Supply Situation of Caelyx 2012 http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2013/04/WC500142510.pdf
10. C.R. Alving, S.C. Kinsky, J.A. Haxby, and C.B. Kinsky Antibody binding and complement fixation by a liposomal model membrane Biochemistry 8 1969 1582 1587
11. S.C. Kinsky, J.A. Haxby, D.A. Zopf, C.R. Alving, and C.B. Kinsky Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten Biochemistry 8 1969 4149 4158
12. J. Szebeni The interaction of liposomes with the complement system Crit. Rev. Ther. Drug Carr. Syst. 15 1998 57 88
13. J. Szebeni, L. Baranyi, S. Savay, J. Milosevits, M. Bodo, R. Bunger, and C.R. Alving The interaction of liposomes with the complement system: in vitro and in vivo assays Methods Enzymol. 373 2003 136 154
14. J. Szebeni, F. Muggia, A. Gabizon, and Y. Barenholz Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention Adv. Drug Deliv. Rev. 63 2011 1020 1030
15. B. Romberg, L. Baranyi, R. Bünger, W.-E. hennink, J. Szebeni, and G. Storm Initial observations on complement activation by poly(amino acid)-coated liposomes B. Romberg, Poly(amino Acid)s: Next-generation Coatings for Long-circulating Liposomes - Doctoral Thesis 2007 Utrecht University Utrecht
16. J. Szebeni, C.R. Alving, L. Baranyi, and R. Bunger Interactions of Liposomes with Complement Leading to Adverse Reactions, Liposome Technology Interactions of Liposomes with the Biological Milieu 3 vol. III 2006 1
17. A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N.M. Rafique, C.R. Alving, and F.M. Muggia Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions Ann. Oncol. 14 2003 1430 1437
18. J. Szebeni Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents Crit. Rev. Ther. Drug Carr. Syst. 18 2001 567 606
19. J. Szebeni Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals Mol. Immunol. 61 2014 163 173
20. G. Blume, and G. Cevc Molecular mechanism of the lipid vesicle longevity in vivo Biochim. Biophys. Acta 1146 1993 157 168
21. M. Vert, and D. Domurado Poly(ethylene glycol): protein-repulsive or albumin-compatible? J. Biomater. Sci. Polym. Ed. 11 2000 1307 1317
22. A.A. Gabizon, and F.M. Muggia Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors M.C. Woodle, S. G, Long-Circulating Liposomes: Old Drugs, New Therapeutics 1998 Landes Bioscience Austin, TX 155 174
23. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies Clin. Pharmacokinet. 42 2003 419 436
24. Y. Barenholz Doxil - The first FDA-approved nano-drug: from and idea to product D. Peer, Handbook of Harnessing Biomaterials in Nanomedicine 2012 Pan Standford Publishing Pte. Ltd. Singapure 335 398
25. ®) J. Liposome Res. 10 2000 347 361
26. J. Szebeni, L. Baranyi, S. Savay, J. Milosevits, R. Bunger, P. Laverman, J.M. Metselaar, G. Storm, A. Chanan-Khan, L. Liebes, F.M. Muggia, R. Cohen, Y. Barenholz, and C.R. Alving Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies J. Liposome Res. 12 2002 165 172
27. S.M. Moghimi, and I. Hamad Liposome-mediated triggering of complement cascade J. Liposome Res. 18 2008 195 209
28. I. Hamad, A.C. Hunter, J. Szebeni, and S.M. Moghimi Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process Mol. Immunol. 46 2008 225 232
29. A.J. Andersen, S.H. Hashemi1, T.L. Andresen, A.C. Hunter, and S.M. Moghimi Complement: alive and kicking nanomedicines J. Biomed. Nanotechnol. 5 2009 364 372
30. J. Szebeni, F. Muggia, and Y. Barenholz Case study: complement activation related hypersensitivity reactions to PEGylated liposomal doxorubicin, experimental and clinical evidence, mechanisms and approaches to inhibition M.A. Dobrovolskaia, S.E. McNeil, Handbook of Immunological Properties of Engineered Nanomaterials second ed. 2015
31. M.P. Dierich The receptors K. Rother, G.O. Till, The Complement System 1988 Springer-Verlag Berlin Heidelberg New York London Paris Tokyo 262 272
32. O. Garbuzenko, S. Zalipsky, M. Qazen, and Y. Barenholz Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers Langmuir 21 2005 2560 2568
33. T.L. Andresen, S.S. Jensen, T. Kaasgaard, and K. Jorgensen Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2 Curr. Drug Deliv. 2 2005 353 362
34. H.Y. Tung, Y.C. Su, B.M. Chen, P.A. Burnouf, W.C. Huang, K.H. Chuang, Y.T. Yan, T.L. Cheng, and S.R. Roffler Selective Delivery of PEGylated Compounds to Tumor Cells by anti-PEG Hybrid Antibodies Mol. Cancer Ther. 14 2015 1317 1326
35. T. Suzuki, M. Ichihara, K. Hyodo, E. Yamamoto, T. Ishida, H. Kiwada, H. Ishihara, and H. Kikuchi Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs Int. J. Pharm. 436 2012 636 643
36. Y. Hashimoto, T. Shimizu, Y. Mima, A.S. Abu Lila, T. Ishida, and H. Kiwada Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs Toxicol. Appl. Pharmacol. 277 2014 30 38
37. A.S. Abu Lila, H. Kiwada, and T. Ishida The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage J. Control Release 172 2013 38 47
38. H. Schellekens, W.E. Hennink, and V. Brinks The immunogenicity of polyethylene glycol: facts and fiction Pharm. Res. 30 2013 1729 1734
39. T. Tagami, Y. Uehara, N. Moriyoshi, T. Ishida, and H. Kiwada Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA J. Control Release 151 2011 149 154
40. T. Ishida, X. Wang, T. Shimizu, K. Nawata, and H. Kiwada PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner J. Control Release 122 2007 349 355
41. K. Sroda, J. Rydlewski, M. Langner, A. Kozubek, M. Grzybek, and A.F. Sikorski Repeated injections of PEG-PE liposomes generate anti-PEG antibodies Cell Mol. Biol. Lett. 10 2005 37 47
42. M.L. Immordino, F. Dosio, and L. Cattel Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomedicine 1 2006 297 315
43. S.M. Moghimi, I.S. Muir, L. Illum, S.S. Davis, and V. Kolb-Bachofen Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum Biochim. Biophys. Acta 1179 1993 157 165
44. S.A. Johnstone, D. Masin, L. Mayer, and M.B. Bally Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages Biochim. Biophys. Acta 1513 2001 25 37
45. American National Standards Institute Association for the Advancement of Medical Instrumentation and International Organization for Standardization, Biological Evaluation of Medical Devices- Part 4: Selection of Tests for Interaction with Blood 2009 ANSI/AAMI/ISO 10993-4:2002/(R) 10 March 2009
46. American National Standards Institute Materials, Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials 1984 ASTM, Publication F2065-00
47. J. Szebeni Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions Eur. J. Nanomed. 5 2012 33 53
48. I. Ramasamy, E. Tran, and A. Farrugia Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations Biologicals 25 1997 87 92
49. A. Suda, Y. Iwaki, and M. Kimura Differentiation of responses to allergenic and irritant compounds in mouse popliteal lymph node assay J. Toxicol. Sci. 25 2000 131 136
50. K. Shinkai, K. Nakamura, N. Tsutsui, Y. Kuninishi, Y. Iwaki, H. Nishida, R. Suzuki, H.W. Vohr, M. Takahashi, K. Takahashi, Y. Kamimura, and E. Maki Mouse popliteal lymph node assay for assessment of allergic and autoimmunity-inducing potentials of low-molecular-weight drugs J. Toxicol. Sci. 24 1999 95 102
51. S.C. Gad The mouse ear swelling test (MEST) in the 1990s Toxicology 93 1994 33 46
52. J.B. Cornacoff, R.V. House, and J.H. Dean Mouse ear swelling test (MEST) Fundam. Appl. Toxicol. 19 1992 157 158
53. S.C. Gad Standard mouse ear swelling test (MEST) Fundam. Appl. Toxicol. 11 1988 732 733
54. I. Kimber, J. Hilton, and P.A. Botham Identification of contact allergens using the murine local lymph node assay: comparisons with the Buehler occluded patch test in guinea pigs J. Appl. Toxicol. 10 1990 173 180
55. M.K. Robinson, T.L. Nusair, E.R. Fletcher, and H.L. Ritz A review of the Buehler guinea pig skin sensitization test and its use in a risk assessment process for human skin sensitization Toxicology 61 1990 91 107
56. J.L. Weaver, D. Staten, J. Swann, G. Armstrong, M. Bates, and K.L. Hastings Detection of systemic hypersensitivity to drugs using standard guinea pig assays Toxicology 193 2003 203 217
57. Quidel MicroVue Complement: Technical Data Sheet for the Pan-Specific C3 Reagent Kit 2014 https://www.quidel.com/sites/default/files/product/documents/microvue-pan-specific-tds.pdf
58. M.A. Seelen, A. Roos, J. Wieslander, T.E. Mollnes, A.G. Sjoholm, R. Wurzner, M. Loos, F. Tedesco, R.B. Sim, P. Garred, E. Alexopoulos, M.W. Turner, and M.R. Daha Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA J. Immunol. Methods 296 2005 187 198
59. G. Bergseth, J.K. Ludviksen, M. Kirschfink, P.C. Giclas, B. Nilsson, and T.E. Mollnes An international serum standard for application in assays to detect human complement activation products Mol. Immunol. 56 2013 232 239
60. Zs Patko, and J. Szebeni Blood cell changes in complement activation-related pseudoallergy Eur. J. Nanomed. 7 2015 233 244
61. A. Ocmant, Y. Peignois, S. Mulier, L. Hanssens, A. Michils, and L. Schandené Flow cytometry for basophil activation markers: the measurement of CD203c up-regulation is as reliable as CD63 expression in the diagnosis of cat allergy J. Immunol. Methods 320 2007 40 48
62. R. Boumiza, A.L. Debard, and G. Monneret The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives Clin. Mol. Allergy 3 2005 9
63. R. Boumiza, G. Monneret, M.F. Forissier, J. Savoye, M.C. Gutowski, W.S. Powell, and J. Bienvenu Marked improvement of the basophil activation test by detecting CD203c instead of CD63 Clin. Exp. Allergy 33 2003 259 265
64. J. Szebeni, J.L. Fontana, N.M. Wassef, P.D. Mongan, D.S. Morse, D.E. Dobbins, G.L. Stahl, R. Bunger, and C.R. Alving Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody Circulation 99 1999 2302 2309
65. M. Bodo, J. Szebeni, L. Baranyi, S. Savay, F. Pearce, C. Alving, and R. Bunger Cerebrovascular involvement in liposome-induced cardiopulmonary distress in pigs J. Liposome Res. 15 2005 3 14
66. J. Szebeni, L. Baranyi, S. Savay, M. Bodo, J. Milosevits, C.R. Alving, and R. Bunger Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function Am. J. Physiol. Heart Circ. Physiol. 290 2006 H1050 H1058
67. M. Bodo, J. Szebeni, L. Baranyi, S. Savay, F. Pearce, C. Alving, and R. Bunger Liposome-induced and complement activation-related changes in cerebrovascular flow in pigs Mol. Immunol. 43 2006 157
68. J. Szebeni, P. Bedocs, D. Csukas, L. Rosivall, R. Bunger, and R. Urbanics A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines Adv. Drug Deliv. Rev. 64 2012 1706 1716
69. J. Szebeni, P. Bedocs, R. Urbanics, R. Bunger, L. Rosivall, M. Tóth, and Y. Barenholz Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model J. Contr. Rel. 160 2012 382 387
70. J. Szebeni, P. Bedocs, Z. Rozsnyay, Z. Weiszhár, R. Urbanics, L. Rosivall, R. Cohen, O. Garbuzenko, G. Báthori, M. Tóth, R. Bünger, and Y. Barenholz Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome Nanomedicine NBM 8 2012 176 184
71. R. Urbanics, P. Bedocs, and J. Szebeni Lessons learned from the porcine CARPA model: constant and variable responses to different nanomedicines and administration protocols Eur. J. Nanomed. 7 2015 219 231
72. N.R. Kuznetsova, C. Sevrin, D. Lespineux, N.V. Bovin, E.L. Vodovozova, T. Mészáros, J. Szebeni, and C. Grandfils Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer J. Control. Release 160 2012 394 400
73. O.M. Merkel, R. Urbanics, P. Bedocs, Z. Rozsnyay, L. Rosivall, M. Toth, T. Kissel, and J. Szebeni In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-grafted-poly (ethylene glycol) block copolymers Biomaterials 32 2011 4936 4942
74. J. Szebeni, J. Fontana, N. Wassef, P. Mongan, D. Morse, G. Stahl, R. Bünger, and C. Alving Liposome-induced and complement-mediated cardiopulmonary distress in pigs as a model of pseudo-allergic reactions to liposomal drugs Mol. Immunol. 35 1998 401
75. D. Csukas, R. Urbanics, G. Weber, L. Rosivall, and J. Szebeni Pulmonary intravascular macrophages: prime suspects as cellular mediators of porcine CARPA Eur. J. Nanomed. 7 2015 27 36
76. A.W. Tang A practical guide to anaphylaxis Am. Fam. Physician 68 2003 1325 1332
77. J. Ring, M. Grosber, M. Mohrenschlager, and K. Brockow Anaphylaxis: acute treatment and management Chem. Immunol. Allergy 95 2010 201 210 10.1159/000315953 Epub 2010 Jun 1
78. J. Szebeni, and Y. Barenholz Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes D. Peer, Handbook of Harnessing Biomaterials in Nanomedicine: Prepara!on,Toxicity, and Applications 2012 Pan Standford Publishing Pte. Ltd. Singapure 309 334
79. J. Szebeni Complement activation by nanomaterials B. Fadeel, Handbook of Safety Assessment of Nanomaterials: From Toxicological Testing to Personalized Medicine 2015 Pan Stanford Publishing Pte. Ltd. 281 310
80. J. Szebeni, and W. Jiskoot Immunological issues with nanomedicines: immunogenicity, hypersensitivity, accelerated clearance and immune suppression V. Torchillin, Handbook of Nanobiomedical Research 2014 World Scientific Singapore 45 73
81. J. Szebeni Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity Toxicology 216 2005 106 121